CONGRESSES
CONGRESSES
Find information on previous and upcoming congresses
View upcoming congresses and filter through abstracts, presentations, and posters from past congresses.
Upcoming congresses
American College of Allergy, Asthma and Immunology (ACAAI)
BioCryst will attend the 2026 American College of Allergy, Asthma and Immunology (ACAAI) from Nov 12 – Nov 16, 2026.
Browse our archive of congress materials
Filter
Showing 144 Materials
-
Reductions in Healthcare Utilization Among Individuals with HAE Who Switched to Berotralstat from Another Prophylaxis
ACAAI | 2026 | HAE -
Hospitalization and Emergency Department Reductions After Initiating Berotralstat, Lanadelumab, or Subcutaneous Plasma-Derived-C1-Inhibitor for Hereditary Angioedema
ACAAI | 2026 | HAE -
Growth-Related Berotralstat Dose Adjustment in Children with Hereditary Angioedema: 48-Week Dosing Experience from APeX-P
ACAAI | 2026 | HAE -
Long-term Safety, Efficacy, and Quality of Life with Navenibart in Hereditary Angioedema: ALPHA-SOLAR Interim Results
ACAAI | 2026 | HAE -
Clinical Outcomes With Navenibart According to Baseline Attack Rate, Body Mass Index, and Age: Results of the ALPHA-STAR Trial
EAACI | 2026 | HAE -
Hereditary Angioedema Attack Frequency and Severity According to Individuals Taking Berotralstat for Long-Term Prophylaxis
EAACI | 2026 | HAE -
Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilising Professional Care in Paediatric Patients Aged 2 to <12 years: APeX-P Results Through 48 Weeks
EAACI | 2026 | HAE -
Reductions in Healthcare Resource Utilization in Adolescents with Hereditary Angioedema on Berotralstat
EAACI | 2026 | HAE -
Hereditary Angioedema Attack Rates among Patients with Normal C1 Esterase Inhibitor Before and After Switching from Another Long-Term Prophylaxis to Berotralstat
EAACI | 2026 | HAE -
Reductions in Hereditary Angioedema Attacks among Patients with C1 Esterase Inhibitor Deficiency who Switched from Another Long-Term Prophylaxis to Berotralstat
EAACI | 2026 | HAE